TY - JOUR T1 - Expression Level of MicroRNA-449a Predicts the Prognosis of Patients With Gastric Cancer JF - Anticancer Research JO - Anticancer Res SP - 239 LP - 244 DO - 10.21873/anticanres.13945 VL - 40 IS - 1 AU - DAICHI ISHIKAWA AU - KOZO YOSHIKAWA AU - CHIE TAKASU AU - HIDEYA KASHIHARA AU - MASAAKI NISHI AU - TAKUYA TOKUNAGA AU - JUN HIGASHIJIMA AU - MITSUO SHIMADA Y1 - 2020/01/01 UR - http://ar.iiarjournals.org/content/40/1/239.abstract N2 - Background: In previous studies, we demonstrated the significant role of microRNA-449a (miR-449a) in colorectal cancer with in vivo and clinical samples. The importance of miR-449a in gastric cancer is still to be elucidated. This study examined the impact of miR-449a expression in tumor tissue and serum and investigated its potential as a prognostic marker in gastric cancer. Materials and Methods: Sixty-six patients with gastric cancer who underwent surgery were included in the study. miR-449a expression in tumor tissue and serum were investigated by real-time polymerase chain reaction analysis. The association of miR-449a expression with clinicopathological factors and patient prognosis were also investigated. Results: miR-449a expression was lower in tumor tissue than non-tumor tissue. miR-449a in tumor tissue negatively correlated with the malignancy of tumor and clinical stage. Increased carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels were seen at significantly higher frequencies in patients with low miR-449a expression. Patients with low miR-449a expression had poorer cancer-specific survival compared to those with high miR-449a expression. The univariate analysis showed that lymphovascular invasion, increased CEA and CA19-9 and a low expression of miR-449a were associated with a poorer 5-year cancer-specific survival. miR-449a expression level in serum correlated to that in tumor tissue and was also associated with tumor malignancy. Conclusion: The miR-449a level in tumor tissue might be useful as a prognostic indicator for patients with gastric cancer and miR-449a in serum appears to reflect its expression in tumor tissue. ER -